Clinical Research Directory
Browse clinical research sites, groups, and studies.
Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).
Sponsor: Pfizer
Summary
This study is to assess the safety and effectiveness of Elranatamab in the real-world clinical settings for the treatment of patients with multiple myeloma in Korea.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2025-06-05
Completion Date
2030-01-31
Last Updated
2025-11-24
Healthy Volunteers
No
Conditions
Interventions
Elranatamab
According to the approved label, the recommended doses are step-up doses of 12 mg on day 1 and 32 mg on day 4, followed by a full treatment dose of 76 mg weekly from week 2 to week 24. For patients who have received at least 24 weeks of treatment and have achieved a response, the dosing interval should transition to an every two week schedule.
Locations (1)
Pfizer
Seoul, South Korea